Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 5/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7584937 | 0.95 | BACE1 (0.60) | BACE1LMNAHTTMEN1ALDH1A1 | |
| SCHEMBL7518412 | 0.90 | BACE1 (0.65) | BACE1LMNAHTTMEN1ALDH1A1 | |
| SCHEMBL7512580 | 0.90 | BACE1 (0.65) | BACE1LMNAHTTMEN1ALDH1A1 | |
| SCHEMBL7518108 | 0.88 | BACE1 (0.62) | BACE1LMNAHTTMEN1ALDH1A1 | |
| SCHEMBL13407706 | 0.86 | BACE1 (0.61) | BACE1LMNAHTTMEN1ALDH1A1 | |
| SCHEMBL7518711 | 0.82 | BACE1 (0.48) | BACE1GRM2CTSD | |
| SCHEMBL17715613 | 0.81 | BACE1 (0.42) | BACE1LMNAHTTALDH1A1CTSD | |
| SCHEMBL17551697 | 0.81 | BACE1 (0.42) | BACE1LMNAALDH1A1CTSD | |
| SCHEMBL17568880 | 0.81 | BACE1 (0.42) | BACE1MEN1ALDH1A1KMT2AGRM2 | |
| SCHEMBL12503319 | 0.81 | BACE1 (0.42) | BACE1LMNAHTTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885LMNA 2420/4885HTT 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.